Compare OSBC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSBC | PHAR |
|---|---|---|
| Founded | 1981 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 885.7M |
| IPO Year | 2014 | 2020 |
| Metric | OSBC | PHAR |
|---|---|---|
| Price | $23.15 | $13.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $23.50 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 358.5K | 4.8K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.20 | $10.04 |
| Revenue Next Year | $3.66 | $2.51 |
| P/E Ratio | ★ $48.40 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.43 | $9.54 |
| 52 Week High | $23.95 | $21.34 |
| Indicator | OSBC | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 63.75 | 57.84 |
| Support Level | $19.21 | $12.98 |
| Resistance Level | N/A | $17.60 |
| Average True Range (ATR) | 0.56 | 0.38 |
| MACD | 0.09 | 0.19 |
| Stochastic Oscillator | 70.61 | 86.30 |
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.